Drug intelligence / Profile preview

ASFV toxoid antigen vaccine

Development stage: Preclinical
Lead developer: Porcine Therapeutics
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous, Intradermal, Oral, Intranasal, Intraperitoneal, Parenteral

Overview

ASFV toxoid antigen vaccine is a purified toxoid antigen subunit vaccine candidate being developed by Kermode Bio, specifically through its Porcine Therapeutics division. The vaccine is designed to prevent African Swine Fever Virus (ASFV) infection in swine, a highly contagious and often fatal viral disease that poses a significant threat to the global pork industry. By utilizing a toxoid approach—where viral toxins or proteins are inactivated but remain immunogenic—the vaccine aims to stimulate a protective immune response in pigs without the safety concerns associated with live-attenuated virus vaccines. It is currently in the preclinical stage of development.

Other names: ASFV purified toxoid antigen subunit vaccine

Targets

ASFV (African swine fever virus)

Beyond the preview

Go deeper on ASFV toxoid antigen vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ASFV toxoid antigen vaccine.

Explore the full profile